Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2 - Concepedia

Concepedia

Publication | Open Access

Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2

DOI Full Paper Access

178

Citations

7

References

2008

Year

Rogério Lilenbaum, Rita Axelrod, Sachdev Thomas, Afshin Dowlati, L. Seigel, Donald G. Albert, Karsten Witt, D. Botkin

Journal of Clinical Oncology

Abstract

Unselected patients with advanced NSCLC and PS 2 are best treated with combination chemotherapy as first-line therapy. Erlotinib may be considered in patients selected by clinical or molecular markers.

References

	Year	Citations

Page 1